There's itch relief. Then there's Zenrelia™ (ilunocitinib tablet).
Zenrelia is an innovative, once daily treatment to break the itch-scratch cycle that lets more dogs get back to normal1*.
Zenrelia is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
Zenrelia targets itch where it starts
Zenrelia works by interrupting key cytokine signaling pathways involved in allergic itch and breaks the itch-scratch cycle2.
Zenrelia offers dogs relief from pruritus associated with allergic and atopic dermatitis1*
*In a Head to Head clinical trial, 77% of Zenrelia-treated dogs achieved clinical remission from pruritus compared to 53% of Apoquel-treated dogs1
Zenrelia improves skin condition2
Zenrelia vs. Placebo
Zenrelia vs. Oclacitnib
Safety
In clinical trials, the most observed adverse events were vomiting, diarrhea and lethargy with a similar frequency in both study groups.
- Zenrelia is indicated for use in dogs at least 12 months of age
- Not for use in dogs with serious infections
- Can be used long term for maintenance therapy
- The use of Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs
- Can be used concomitantly with many medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives, parasiticides, antifungals and allergen-specific immunotherapy
- The use of Zenrelia has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents
Dosing and administration
A hypoallergenic, flavorless, oral tablet
No need to load or taper dose: can stop/start for short or long-term use
Once daily administration, with or without food
Dosed at 0.27–0.36 mg/lb (0.6–0.8 mg/kg)
Sources of Zen
Stay informed on everything Zenrelia
INDICATIONS
Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION
Read the entire package insert before using this drug, including the Boxed Warning.
For Full prescribing information call 1 888 545 5973 or visit http://www.elancolabels.com/us/zenrelia
WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.
